If you or a loved one developed PML after taking Tysabri, you may be wondering how common certain symptoms or outcomes are. Medical case reports have documented recurring patterns in how PML presents and progresses in these patients. Building on established clinical knowledge about Tysabri-associated PML, this page reviews the patterns described in published case series to help you understand what the literature shows.
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for moderate to severe active Crohn's disease in adults. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri due to this risk, emphasizing that healthcare professionals must monitor patients for any new sign or symptom suggestive of PML and withhold dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected therapeutic benefit when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML presents with subacute neurological deficits that vary depending on the location of brain lesions. Common symptoms include progressive weakness, cognitive decline, visual disturbances (such as hemianopia), ataxia, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). In multiple sclerosis patients, an MRI should be obtained before initiating Tysabri to help differentiate subsequent MS symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For Crohn's disease patients, a baseline brain MRI may also be useful, though pre-existing lesions are uncommon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is a humanized monoclonal antibody that binds to the alpha-4 subunit of integrins, blocking adhesion molecules on leukocytes and preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for MS and Crohn's disease. However, this immune surveillance impairment allows latent JCV, which is present in many individuals, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients with anti-JCV antibodies, indicating prior exposure to the virus, and increases with cumulative treatment duration.
PML associated with Tysabri carries a grave prognosis, as the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The primary treatment is prompt discontinuation of Tysabri and supportive care. In some cases, plasma exchange or immunoadsorption may be used to rapidly remove natalizumab from the circulation, potentially restoring immune function. However, immune reconstitution inflammatory syndrome (IRIS) can occur after drug withdrawal, causing paradoxical worsening of neurological symptoms as the immune system attacks JCV-infected cells. There is no specific antiviral therapy for JCV, so management focuses on controlling IRIS with corticosteroids and providing rehabilitative support.
PML can occur at any time during Tysabri treatment, but the risk increases with longer exposure, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported after discontinuation of Tysabri in patients who had no signs of PML at the time of stopping therapy. Therefore, monitoring for new neurological symptoms should continue for at least six months following discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This delayed presentation underscores the need for prolonged vigilance.
The FDA boxed warning clearly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It identifies specific risk factors and mandates immediate withholding of dosing at first suspicion of PML. The TOUCH Prescribing Program ensures that prescribers and patients are educated about these risks. However, despite these measures, PML remains a devastating complication, and the adequacy of warnings is a matter of ongoing clinical and regulatory attention. The label also notes that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease, as this may further elevate risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
The prognosis for severe PML after Tysabri is grave, as the infection usually leads to death or severe disability. Prompt discontinuation of Tysabri and supportive care are critical, but there is no specific antiviral therapy for JCV. Management focuses on controlling immune reconstitution inflammatory syndrome (IRIS) with corticosteroids and providing rehabilitative support.
PML can occur at any time during Tysabri treatment, but the risk increases with longer exposure, particularly beyond two years. PML has also been reported after discontinuation of Tysabri, so monitoring for new neurological symptoms should continue for at least six months after stopping therapy.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.